Literature DB >> 31611364

In Vitro Activities of β-Lactam-β-Lactamase Inhibitor Antimicrobial Agents against Cystic Fibrosis Respiratory Pathogens.

Lindsay J Caverly1, Theodore Spilker1, Linda M Kalikin1, Terri Stillwell1, Carol Young2, David B Huang3,4, John J LiPuma5.   

Abstract

We tested the in vitro activities of ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam, piperacillin-tazobactam, and 11 other antimicrobial agents against 420 Burkholderia, Achromobacter, Stenotrophomonas, and Pandoraea strains, 89% of which were cultured from respiratory specimens from persons with cystic fibrosis. Among the β-lactam-β-lactamase inhibitor agents, meropenem-vaborbactam had the greatest activity against Burkholderia and Achromobacter, including multidrug-resistant and extensively-drug-resistant strains. None of the newer β-lactam-β-lactamase combination drugs showed increased activity compared to that of the older agents against Stenotrophomonas maltophilia or Pandoraea spp.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  ceftazidime-avibactam; ceftolozane-tazobactam; cystic fibrosis; meropenem-vaborbactam; respiratory tract infection

Year:  2019        PMID： 31611364      PMCID： PMC7187596          DOI： 10.1128/AAC.01595-19

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  12 in total

1.  Overcoming an Extremely Drug Resistant (XDR) Pathogen: Avibactam Restores Susceptibility to Ceftazidime for Burkholderia cepacia Complex Isolates from Cystic Fibrosis Patients.

Authors:  Krisztina M Papp-Wallace; Scott A Becka; Elise T Zeiser; Nozomi Ohuchi; Maria F Mojica; Julian A Gatta; Monica Falleni; Delfina Tosi; Elisa Borghi; Marisa L Winkler; Brigid M Wilson; John J LiPuma; Michiyoshi Nukaga; Robert A Bonomo
Journal:  ACS Infect Dis       Date:  2017-03-30       Impact factor: 5.084

2.  Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance.

Authors:  A-P Magiorakos; A Srinivasan; R B Carey; Y Carmeli; M E Falagas; C G Giske; S Harbarth; J F Hindler; G Kahlmeter; B Olsson-Liljequist; D L Paterson; L B Rice; J Stelling; M J Struelens; A Vatopoulos; J T Weber; D L Monnet
Journal:  Clin Microbiol Infect       Date:  2011-07-27       Impact factor: 8.067

Review 3.  Cystic fibrosis respiratory microbiota: unraveling complexity to inform clinical practice.

Authors:  Lindsay J Caverly; John J LiPuma
Journal:  Expert Rev Respir Med       Date:  2018-09-03       Impact factor: 3.772

Review 4.  Past and Present Perspectives on β-Lactamases.

Authors:  Karen Bush
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

5.  Development of a recA gene-based identification approach for the entire Burkholderia genus.

Authors:  George W Payne; Peter Vandamme; Sara H Morgan; John J Lipuma; Tom Coenye; Andrew J Weightman; T Hefin Jones; Eshwar Mahenthiralingam
Journal:  Appl Environ Microbiol       Date:  2005-07       Impact factor: 4.792

6.  Identification and distribution of Achromobacter species in cystic fibrosis.

Authors:  Theodore Spilker; Peter Vandamme; John J Lipuma
Journal:  J Cyst Fibros       Date:  2012-11-07       Impact factor: 5.482

Review 7.  The changing microbial epidemiology in cystic fibrosis.

Authors:  John J Lipuma
Journal:  Clin Microbiol Rev       Date:  2010-04       Impact factor: 26.132

8.  Use of the gyrB gene for the identification of Pandoraea species.

Authors:  Tom Coenye; John J LiPuma
Journal:  FEMS Microbiol Lett       Date:  2002-02-19       Impact factor: 2.742

9.  Changing Epidemiology of the Respiratory Bacteriology of Patients With Cystic Fibrosis.

Authors:  Elizabeth L Salsgiver; Aliza K Fink; Emily A Knapp; John J LiPuma; Kenneth N Olivier; Bruce C Marshall; Lisa Saiman
Journal:  Chest       Date:  2016-01-12       Impact factor: 9.410

10.  Comparative assessment of genotyping methods for epidemiologic study of Burkholderia cepacia genomovar III.

Authors:  Tom Coenye; Theodore Spilker; Alissa Martin; John J LiPuma
Journal:  J Clin Microbiol       Date:  2002-09       Impact factor: 5.948
View more
  10 in total

1.  In Vitro Antibacterial Activity and In Vivo Efficacy of Sulbactam-Durlobactam against Pathogenic Burkholderia Species.

Authors:  Krisztina M Papp-Wallace; Adam B Shapiro; Scott A Becka; Elise T Zeiser; John J LiPuma; Douglas J Lane; Rekha G Panchal; John P Mueller; John P O'Donnell; Alita A Miller
Journal:  Antimicrob Agents Chemother       Date:  2021-02-17       Impact factor: 5.191

Review 2.  New β-Lactam-β-Lactamase Inhibitor Combinations.

Authors:  Dafna Yahav; Christian G Giske; Alise Grāmatniece; Henrietta Abodakpi; Vincent H Tam; Leonard Leibovici
Journal:  Clin Microbiol Rev       Date:  2020-11-11       Impact factor: 26.132

Review 3.  Achromobacter Infections and Treatment Options.

Authors:  Burcu Isler; Timothy J Kidd; Adam G Stewart; Patrick Harris; David L Paterson
Journal:  Antimicrob Agents Chemother       Date:  2020-10-20       Impact factor: 5.191

Review 4.  New Perspectives on Antimicrobial Agents: Cefiderocol.

Authors:  Erin K McCreary; Emily L Heil; Pranita D Tamma
Journal:  Antimicrob Agents Chemother       Date:  2021-07-16       Impact factor: 5.191

5.  Immunoinformatic Approach to Contrive a Next Generation Multi-Epitope Vaccine Against Achromobacter xylosoxidans Infections.

Authors:  Kashaf Khalid; Umar Saeed; Mohammad Aljuaid; Mohammad Ishtiaq Ali; Awais Anjum; Yasir Waheed
Journal:  Front Med (Lausanne)       Date:  2022-07-11

6.  Activity of Imipenem-Relebactam against Multidrug- and Extensively Drug-Resistant Burkholderia cepacia Complex and Burkholderia gladioli.

Authors:  Scott A Becka; Elise T Zeiser; John J LiPuma; Krisztina M Papp-Wallace
Journal:  Antimicrob Agents Chemother       Date:  2021-08-09       Impact factor: 5.191

Review 7.  The Bactericidal Tandem Drug, AB569: How to Eradicate Antibiotic-Resistant Biofilm Pseudomonas aeruginosa in Multiple Disease Settings Including Cystic Fibrosis, Burns/Wounds and Urinary Tract Infections.

Authors:  Daniel J Hassett; Rhett A Kovall; Michael J Schurr; Nalinikanth Kotagiri; Harshita Kumari; Latha Satish
Journal:  Front Microbiol       Date:  2021-06-17       Impact factor: 5.640

8.  Advances in the Microbiology of Stenotrophomonas maltophilia.

Authors:  Joanna S Brooke
Journal:  Clin Microbiol Rev       Date:  2021-05-26       Impact factor: 50.129

9.  Avibactam potentiated the activity of both ceftazidime and aztreonam against S. maltophilia clinical isolates in vitro.

Authors:  Qiuxia Lin; Hua Zou; Xian Chen; Menglu Wu; Deyu Ma; Hanbing Yu; Siqiang Niu; Shifeng Huang
Journal:  BMC Microbiol       Date:  2021-02-22       Impact factor: 3.605

10.  In Vitro Activity of 22 Antibiotics against Achromobacter Isolates from People with Cystic Fibrosis. Are There New Therapeutic Options?

Authors:  Clémence Beauruelle; Claudie Lamoureux; Arsid Mashi; Sophie Ramel; Jean Le Bihan; Thomas Ropars; Anne Dirou; Anandadev Banerjee; Didier Tandé; Hervé Le Bars; Geneviève Héry-Arnaud
Journal:  Microorganisms       Date:  2021-11-30
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.